Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Related Citations for PubMed (Select 22130974)

1.

Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis.

Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde CM, van Tol MJ, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA.

Arthritis Rheum. 2012 May;64(5):1323-8. doi: 10.1002/art.33489.

2.

Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis.

van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, van Schaardenburg D.

Arthritis Rheum. 2011 Nov;63(11):3226-33. doi: 10.1002/art.30537.

3.

Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study.

Teng YK, Verburg RJ, Verpoort KN, Diepenhorst GM, Bajema IM, van Tol MJ, Jol-van der Zijde EC, Toes RE, Huizinga TW, van Laar JM.

Arthritis Res Ther. 2007;9(5):R106.

4.

Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.

van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, Drijfhout JW, Huizinga TW, Toes RE, Pruijn GJ.

Ann Rheum Dis. 2010 Aug;69(8):1554-61. doi: 10.1136/ard.2009.124537. Epub 2010 May 6.

PMID:
20448290
5.

Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis.

Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, Engström M, Grunewald J, Nyren S, Eklund A, Klareskog L, Sköld CM, Catrina AI.

Arthritis Rheumatol. 2014 Jan;66(1):31-9. doi: 10.1002/art.38201.

PMID:
24449573
6.

Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease.

Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, Elias B, Ménard HA, Newkirk M, Fritzler MJ, Toes RE, Huizinga TW, El-Gabalawy HS.

Arthritis Rheum. 2008 Oct;58(10):3000-8. doi: 10.1002/art.23763.

7.

Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients.

Barra L, Scinocca M, Saunders S, Bhayana R, Rohekar S, Racapé M, Coles R, Cairns E, Bell DA.

Arthritis Rheum. 2013 Jun;65(6):1439-47. doi: 10.1002/art.37911.

8.

Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis.

Suwannalai P, Britsemmer K, Knevel R, Scherer HU, Levarht EW, van der Helm-van Mil AH, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA.

Ann Rheum Dis. 2014 Jan;73(1):270-6. doi: 10.1136/annrheumdis-2012-202615. Epub 2013 Mar 5.

PMID:
23463689
9.

Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study.

Arkema EV, Goldstein BL, Robinson W, Sokolove J, Wagner CA, Malspeis S, Rosner B, Grodstein F, Karlson EW, Costenbader KH.

Arthritis Res Ther. 2013 Oct 23;15(5):R159. doi: 10.1186/ar4342.

10.

Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.

van der Woude D, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Thomson W, Worthington J, van der Helm-van Mil AH, de Vries RR.

Arthritis Rheum. 2009 Apr;60(4):916-23. doi: 10.1002/art.24385.

11.

Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis.

Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, Roos J, Bajema IM, van der Voort EI, Huizinga TW, Toes RE.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2586-91. doi: 10.1073/pnas.0913054107. Epub 2010 Jan 25. Retraction in: Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, Roos J, Bajema IM, van der Voort EI, Huizinga TW, Toes RE. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20345.

12.

Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations.

van der Woude D, Lie BA, Lundström E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, Verduijn W, Nordang GB, Alfredsson L, Klareskog L, Pascual-Salcedo D, Gonzalez-Gay MA, Lopez-Nevot MA, Valero F, Roep BO, Huizinga TW, Kvien TK, Martín J, Padyukov L, de Vries RR, Toes RE.

Arthritis Rheum. 2010 May;62(5):1236-45. doi: 10.1002/art.27366.

13.

Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens.

Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA.

Ann Rheum Dis. 2011 Feb;70(2):373-9. doi: 10.1136/ard.2010.135509. Epub 2010 Nov 10.

PMID:
21068094
14.

Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.

Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engström A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmström V.

Arthritis Rheum. 2010 Jan;62(1):44-52. doi: 10.1002/art.25036.

15.

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.

Arthritis Rheum. 2009 Aug;60(8):2232-41. doi: 10.1002/art.24716.

16.

Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.

Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE.

Arthritis Rheum. 2006 Dec;54(12):3799-808.

17.

Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis.

Lundström E, Källberg H, Smolnikova M, Ding B, Rönnelid J, Alfredsson L, Klareskog L, Padyukov L.

Arthritis Rheum. 2009 Apr;60(4):924-30. doi: 10.1002/art.24410.

18.

Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives.

Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D, Markland J, Robinson D, Elias B, Newkirk M, Toes RM, Huizinga TW, El-Gabalawy HS.

J Rheumatol. 2010 Jun;37(6):1105-12. doi: 10.3899/jrheum.091323. Epub 2010 May 1.

PMID:
20436074
19.

The ACPA recognition profile and subgrouping of ACPA-positive RA patients.

Willemze A, Böhringer S, Knevel R, Levarht EW, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, van der Helm-van Mil AH, Huizinga TW, Toes RE, Trouw LA.

Ann Rheum Dis. 2012 Feb;71(2):268-74. doi: 10.1136/annrheumdis-2011-200421. Epub 2011 Oct 13.

PMID:
21998120
20.

Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis.

Cantaert T, Brouard S, Thurlings RM, Pallier A, Salinas GF, Braud C, Klarenbeek PL, de Vries N, Zhang Y, Soulillou JP, Tak PP, Baeten D.

Arthritis Rheum. 2009 Jul;60(7):1944-56. doi: 10.1002/art.24635.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk